See the DrugPatentWatch profile for belsomra
Suvorexant, marketed as Belsomra, is not yet available in generic form.
When Might Generic Belsomra Become Available?
The earliest date for generic Belsomra to become available is likely around 2027, as patent protections are in place. Specific patent expiration dates can vary and are often subject to legal challenges, which could alter the timeline. Information on the exact patent status and potential generic entry dates can be found on sites like DrugPatentWatch.com [1].
What is Belsomra Used For?
Belsomra is a medication prescribed to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [2]. It works by blocking the wake-promoting action of orexins in the brain [3].
How Does Belsomra Work?
Belsomra's mechanism of action involves acting as a dual orexin receptor antagonist. Orexins are neuropeptides that play a role in regulating wakefulness. By inhibiting the binding of orexins to their receptors (OX1R and OX2R), Belsomra reduces the signaling that promotes wakefulness, thereby facilitating sleep [3].
What Are the Potential Side Effects of Belsomra?
Common side effects associated with Belsomra include drowsiness and headache. More serious, though less common, side effects can include complex sleep behaviors such as sleep-walking or sleep-driving, and daytime impairment, even when taken as prescribed [2]. Patients are advised to use caution when performing activities requiring mental alertness, such as driving, on the day after taking the medication [2].
Are There Alternatives to Belsomra for Insomnia?
Yes, there are several alternative treatments for insomnia, including other prescription medications, over-the-counter sleep aids, and non-pharmacological approaches. Cognitive Behavioral Therapy for Insomnia (CBT-I) is often recommended as a first-line treatment and can be as effective as medication for chronic insomnia [4]. Other prescription medications for insomnia target different neurotransmitter systems.
Who Manufactures Belsomra?
Belsomra is manufactured by Merck & Co., Inc. [2].
What Are the Key Patents for Belsomra?
The patent landscape for Belsomra is complex and involves multiple patents covering the compound itself, its methods of use, and formulations. These patents are crucial for the drug's market exclusivity. DrugPatentWatch.com tracks these patents and their expiration dates [1].
What is the Cost of Belsomra?
The cost of Belsomra can vary significantly depending on insurance coverage, dosage, and pharmacy. Without insurance, the price can be substantial. Generic versions, when available, typically offer a lower cost alternative.
What are the Risks Associated with Belsomra?
Beyond the side effects mentioned, Belsomra carries a risk of potential abuse or dependence, though it is generally considered to have a lower risk profile in this regard compared to older sedative-hypnotics. There is also a boxed warning for abnormal thinking and behavioral changes, and complex sleep behaviors. Patients with a history of depression or suicidal thoughts should be closely monitored [2].
How Does Belsomra Compare to Other Sleep Medications?
Belsomra belongs to a class of drugs called orexin receptor antagonists, which is distinct from older classes like benzodiazepines and non-benzodiazepine hypnotics (e.g., Ambien, Lunesta). Unlike some other sleep medications that broadly suppress the central nervous system, Belsomra targets the specific wakefulness system mediated by orexins. This mechanism is thought to offer a different side effect profile, particularly concerning next-day impairment and abuse potential [3].
Sources:
[1] DrugPatentWatch.com
[2] Belsomra Prescribing Information
[3] U.S. Food and Drug Administration (FDA) Approval Information for Belsomra
[4] National Institutes of Health (NIH) - Insomnia Treatment